Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

Arthritis and Rheumatism

Volumn 58, Issue 2 SUPPL., 2008, Pages

  Elliott, Michael J ^a   Maini, Ravinder N ^a   Feldmann, Marc ^a   Long Fox, Alice ^a   Charles, Peter ^b   Katsikis, Peter ^a   Brennan, Fionula M ^a   Walker, Jean ^a   Bijl, Hanny ^c   Ghrayeb, John ^c   Woody, James N ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^c CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; HISTORY; HUMAN; IMMUNOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RHEUMATOID ARTHRITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HISTORY, 20TH CENTURY; HUMANS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42949129578     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.23362     Document Type: Article

References (42)

1. Pincus T, Callahan LF: Taking mortality in rheumatoid arthritis seriously: predictive markers, socioeconomic status and comorbidity. J Rheumatol 13:841-845, 1986
2. Scott DL, Symmons DPM, Coulton BL, Popert AJ: Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet 1:1108-1111, 1987
3. Erhardt CC, Mumford PA, Venables PJW, Maini RN: Factors predicting a poor life prognosis in rheumatoid arthritis: an eight year prospective study. Ann Rheum Dis 48:7-13, 1989
4. Herzog C, Walker C, Muller W, Rieber P, Reiter C, Riethmuller G, Wassmer P, Stockinger H, Madic O, Pichler W: Anti-CD4 antibody treatment of patients with rheumatoid arthritis: I. Effect on clinical course and circulating T cells. J Autoimmun 2:627-642, 1989
5. Goldberg D, Morel P, Chatenoud L, Boitard C, Menkes CJ, Bertoye P, Revillard J, Bach J: Immunological effects of high dose administration of anti-CD4 antibody in rheumatoid arthritis patients. J Autoimmun 4:617-630, 1991
6. Horneff G, Burmester GR, Emmrich F, Kalden JR: Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody. Arthritis Rheum 34:129-140, 1991
7. Kirkham BW, Pitzalis C, Kingsley GH, Chikanza IC, Sabharwal S, Barbatis C, Grahame R, Gibson T, Amlot PL, Panayi GS: Monoclonal antibody treatment in rheumatoid arthritis: the clinical and immunological effects of a CD7 monoclonal antibody. Br J Rheumatol 30:459-463, 1991
8. Reiter C, Kakavand B, Rieber EP, Schattenkirchner M, Riethmüller G, Krüger K: Treatment of rheumatoid arthritis with monoclonal CD4 antibody M-T151: clinical results and immunopharmacologic effects in an open study, including repeated administration. Arthritis Rheum 34:525-536, 1991
9. Wendling D, Wijdenes J, Racadot E, Morel-Fourrier B: Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. J Rheumatol 18:325-327, 1991
10. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogen MT, Cobbold SP, Waldmann H: Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340:748-752, 1992
11. Ziff M: Rheumatoid arthritis: its present and future. J Rheumatol 17:127-133, 1990
12. Fontana A, Hengartner H, Weber E, Fehr K, Grob PJ, Cohen G: Interleukin-1 activity in the synovial fluid of patients with rheumatoid arthritis. Rheumatol Int 2:49-53, 1982
13. Buchan G, Barrett K, Turner M, Chantry D, Maini RN, Feldmann M: Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 73:449-453, 1988
14. Chu CQ, Field M, Feldmann M, Maini RN: Localization of tumor necrosis factor α in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 34:1125-1132, 1991
15. Hirano T, Matsuda T, Turner M, Miyasaka N, Buchan G, Tang B, Sato K, Shimizu M, Maini R, Feldmann M, Kishimoto T: Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol 18:1797-1801, 1988
16. Xu WD, Firestein GS, Taetle R, Kaushansky K, Zvaifler NJ: Cytokines in chronic inflammatory arthritis, II: Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J Clin Invest 83:876-882, 1989
17. Brennan FM, Zachariae COC, Chantry D, Larsen CG, Turner M, Maini RN, Matsushima K, Feldmann M: Detection of interleukin-8 biologic activity in synovial fluids from patients with rheumatoid arthritis and production of interleukin-8 mRNA by isolated synovial cells. Eur J Rheumatol 20:2141-2144, 1990
18. Brennan FM, Chantry D, Turner M, Foxwell B, Maini RN, Feldmann M: Detection of transforming growth factor-β in rheumatoid arthritis synovial tissue: lack of effect on spontaneous cytokine production in joint cell cultures. Clin Exp Immunol 81:278-285, 1990
19. Chu CQ, Field M, Abney E, Zheng RQH, Allard S, Feldmann M, Maini RN: Transforming growth factor-β1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol 86:380-386, 1991
20. Kissonerghis AM, Maini RN, Feldmann M: High rate of HLA class II mRNA synthesis in rheumatoid arthritis joints and its persistence in culture: down regulation by recombinant interleukin-2. Stand J Immunol 29:73-82, 1989
21. Brennan FM, Chantry D, Jackson A, Maini RN, Feldmann M: Inhibitory effects of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 2:244-247, 1989
22. Haworth C, Brennan FM, Chantry D, Turner M, Maini RN, Feldmann M: Expression of granulocyte-macrophage colony-stimulating factor (GM-CSF) in rheumatoid arthritis: regulation by tumour necrosis factor-α. Eur J Immunol 21:2575-2579, 1991
23. Brennan FM, Gibbons DL, Mitchell T, Cope AP, Maini RN, Feldmann M: Enhanced expression of tumour necrosis factor receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur J Immunol 22:1907-1912, 1992
24. Deleuran BW, Chu C-Q, Field M, Brennan FM, Mitchell T, Feldmann M, Maini RN: Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum 35:1170-1178, 1992
25. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, Kollias G: Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 10:4025-4031, 1991
26. Williams RO, Feldmann M, Maini RN: Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 89:9784-9788, 1992
27. Feldmann M, Brennan FM, Chantry D, Haworth C, Turner M, Abney E, Buchan G, Barrett K, Barkley D, Chu A, Field M, Maini RN: Cytokine production in the rheumatoid joint: implications for treatment. Ann Rheum Dis 49:480-486, 1990
28. Brennan FM, Maini RN, Feldmann M: TNFα: a pivotal role in rheumatoid arthritis? Br J Rheumatol 31:293-298, 1992
29. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, Medsger TA Jr, Mitchell DM, Neustadt DH, Pinals RS, Schaller JG, Sharp JT, Wilder RL, Hunder GG: The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315-324, 1988
30. Mallya RK, Mace BEW: The assessment of disease activity in rheumatoid arthritis using a multivariate analysis. Rheumatol Rehabil 20:14-17, 1981
31. Steinbrocker O, Traeger CH, Batterman RC: Therapeutic criteria in rheumatoid arthritis. JAMA 140:659-662, 1949
32. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grieveson P, Buchanan WW: Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med 147:393-406, 1968
33. Fuchs HA, Brooks RH, Callahan LF, Pincus T: A simplified twenty-eight-joint quantitative articular index in rheumatoid arthritis. Arthritis Rheum 32:531-537, 1989
34. Kirwan JR, Reeback JS: Stanford health assessment questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 25:206-209, 1986
35. Paulus HE, Egger MJ, Ward JR, Williams HJ, and the Cooperative Systematic Studies of Rheumatic Diseases Group: Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. Arthritis Rheum 33:477-484, 1990
36. Espevik T, Nissen-Meyer J: A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumour necrosis factor from human monocytes. J Immunol Methods 95:99-105, 1986
37. Havell EA: Evidence that tumour necrosis factor has an important role in antibacterial resistance. J Immunol 143:2894-2899, 1989
38. Fong Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, Kenney JS, Lee AT, Kuo GC, Allison AC, Lowry SF, Cerami A: Antibodies to cachectin/tumour necrosis factor reduce interleukin-1β and interleukin-6 appearance during lethal bacteremia. J Exp Med 170:1627-1631, 1989
39. Guerne P-A, Juraw BL, Vaughan JH, Carson DA, Lotz M: Synovium as a source of interleukin-6 in vivo: contribution to local and systemic manifestations of arthritis. J Clin Invest 83:585-592, 1989
40. Roux-Lombard P, Steiner G, and the Cytokine Consensus Study Group Of The European Workshop For Rheumatology Research: Preliminary report on cytokine determination in human synovial fluids: a consensus study of the European Workshop for Rheumatology Research. Clin Exp Rheumatol 10:515-520, 1992
41. Kingsley G, Panayi G, Lanchbury J: Immunotherapy of rheumatic diseases: practice and prospects. Immunol Today 12:177-179, 1991
42. Trentham DE: Immunotherapy and other novel therapies. Curr Opin Rheumatol 3:369-372, 1991